Triglyceride Reduction Guidelines

Introduction to Triglyceride Management

The American College of Cardiology recommends that all patients with triglycerides ≥150 mg/dL should have triglycerides reduced through lifestyle modifications, with pharmacologic therapy intensity determined by absolute triglyceride level and cardiovascular risk stratification 1, 2, 3

For patients with severe to very severe hypertriglyceridemia (≥500 mg/dL), immediate pharmacologic intervention is mandatory regardless of cardiovascular risk to prevent acute pancreatitis, which occurs in 14% of patients at this level 1, 2, 4
The American College of Cardiology suggests initiating fenofibrate 54-160 mg daily as first-line therapy before addressing LDL cholesterol for patients with severe to very severe hypertriglyceridemia 1, 2, 3
The primary goal for patients with severe to very severe hypertriglyceridemia is rapid reduction to <500 mg/dL to eliminate pancreatitis risk, followed by further reduction to <200 mg/dL for cardiovascular protection 1, 3
For patients with moderate hypertriglyceridemia (200-499 mg/dL), those with 10-year ASCVD risk ≥7.5%, established cardiovascular disease, or diabetes should receive statin therapy as first-line, providing 10-30% dose-dependent triglyceride reduction plus proven cardiovascular benefit 1, 2, 4

The American College of Cardiology recommends that all patients with prior MI, stroke, or documented coronary artery disease should have triglycerides reduced to <150 mg/dL through statin therapy, with icosapent ethyl added if triglycerides remain ≥150 mg/dL on maximally tolerated statins 1, 3
Diabetic patients aged 40-75 years require statin therapy regardless of baseline triglyceride levels, as diabetes itself is a high-risk condition 1, 2, 4

Uncontrolled diabetes mellitus must be optimized before adding lipid medications—hyperglycemia should be treated first, then hypertriglyceridemia re-evaluated 1, 2, 4
The American College of Cardiology suggests screening for hypothyroidism, chronic kidney disease, nephrotic syndrome, and chronic liver disease, as these conditions elevate triglycerides and require specific treatment 1, 4, 5

The American College of Cardiology advises against delaying fibrate therapy while attempting lifestyle modifications alone when triglycerides ≥500 mg/dL—pharmacologic intervention is mandatory to prevent pancreatitis 1, 2, 3
The American College of Cardiology recommends against starting with statin monotherapy when triglycerides ≥500 mg/dL—statins provide only 10-30% triglyceride reduction and are insufficient for preventing pancreatitis at this level 1, 2
The American College of Cardiology suggests against using gemfibrozil when combining with statins—fenofibrate has a significantly better safety profile with lower myopathy risk 1, 3